difference between cilacar 10/50 ng and telvas beta 50
Reading File
Finding Sources
Finding Sources
Searching the Web
Cilacar 10 50ng cilnidipine vs Telvas Beta 50 telmisartan metoprolol difference uses
Finding Sources
Finding Sources
Finding Sources
Here is a detailed comparison of both medications:
Cilacar 10/50ng vs Telvas Beta 50
What are they?
| Feature | Cilacar 10/50ng | Telvas Beta 50 |
|---|---|---|
| Brand | Cilacar (Elder Pharma) | Telvas Beta (Glenmark) |
| Generic name | Cilnidipine 10 mg | Telmisartan 40/80 mg + Metoprolol succinate 50 mg |
| Drug class | Dual L/N-type Calcium Channel Blocker (CCB) | ARB (Angiotensin Receptor Blocker) + Beta-1 Selective Blocker |
| Number of drugs | Single agent | Combination of 2 drugs |
Mechanism of Action
Cilacar 10/50ng (Cilnidipine):
- Blocks both L-type (vascular smooth muscle) and N-type (neuronal/sympathetic) calcium channels - this dual blockade is unique among CCBs
- L-type blockade: relaxes arterial smooth muscle → vasodilation → lowers BP
- N-type blockade: suppresses sympathetic nerve terminals → reduces norepinephrine release → prevents reflex tachycardia (a key advantage over amlodipine/nifedipine)
- Also reduces intraglomerular pressure by dilating efferent arterioles → antiproteinuric effect
Telvas Beta 50 (Telmisartan + Metoprolol succinate):
- Telmisartan (ARB): Blocks AT1 receptors → prevents angiotensin II from causing vasoconstriction and aldosterone release → lowers BP + reduces fluid retention. Also has partial PPAR-gamma agonist activity → metabolic benefits (insulin sensitivity). Longest half-life among ARBs (~24 hours)
- Metoprolol succinate (Beta-blocker): Selectively blocks beta-1 adrenergic receptors → slows heart rate, reduces cardiac output and renin release → lowers BP
Key Differences
| Parameter | Cilacar 10/50ng | Telvas Beta 50 |
|---|---|---|
| Primary indication | Hypertension | Hypertension + heart rate control |
| Heart rate | No direct slowing effect (N-type blockade prevents reflex tachycardia) | Significantly reduces heart rate |
| Proteinuria/CKD | Beneficial - reduces efferent arteriolar tone, antiproteinuric | Telmisartan also renoprotective via RAAS blockade |
| Diabetic patients | Preferred - N-type blockade may improve insulin sensitivity; no metabolic side effects | Telmisartan is safe; metoprolol may mask hypoglycemia symptoms, slightly worsen lipid profile |
| Heart failure | Not first-line; can cause ankle edema | Preferred - metoprolol reduces mortality in HFrEF; telmisartan reduces cardiac remodeling |
| Angina / CAD | Some benefit via vasodilation | Preferred - metoprolol is a first-line anti-anginal |
| Ankle edema | Can cause (vasodilation effect) | Less likely |
| Reflex tachycardia | Does NOT cause (N-type blockade) | Does NOT cause (metoprolol slows HR) |
| Cough | No | No (ARBs don't cause cough unlike ACE inhibitors) |
| COPD/Asthma | Safe | Use with caution (metoprolol is beta-1 selective but still risk at higher doses) |
| Half-life | ~8-10 hours | Telmisartan ~24h; Metoprolol succinate ~7h (extended release) |
| Pregnancy | Avoid (like all antihypertensives in pregnancy) | Contraindicated (ARBs are Category D) |
When to Prefer Which?
Choose Cilacar (Cilnidipine) when:
- Hypertension with tachycardia (N-type blockade prevents reflex tachycardia)
- Diabetic nephropathy/CKD with proteinuria
- Patient intolerant to RAAS blockers or beta-blockers
- Elderly patients (smooth BP control without heart rate drop)
- Hypertension + diabetes (no masking of hypoglycemia)
Choose Telvas Beta (Telmisartan + Metoprolol) when:
- Hypertension with high resting heart rate or tachyarrhythmia
- Hypertension + coronary artery disease / angina
- Hypertension + heart failure with reduced ejection fraction (HFrEF)
- Hypertension + post-MI patients
- Metabolic syndrome (telmisartan's PPAR-gamma effect)
- Patients needing both RAAS and sympathetic blockade
Bottom Line
Both are antihypertensives, but they work through completely different pathways and serve different patient profiles. Cilacar is a single CCB with a unique N-type advantage, making it suitable for hypertension with tachycardia or diabetic kidney disease. Telvas Beta is a two-drug combination targeting both the RAAS system and adrenergic drive, making it better suited for hypertension with ischemic heart disease or heart failure.
Note: "50ng" in Cilacar 10/50ng likely refers to the 50 nanogram/50 mcg variant of cilnidipine being discussed in a particular context, or it may be a specific formulation variant - consult the product insert for exact dosing. Standard Cilacar comes in 5 mg and 10 mg tablets.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Brenner & Rector's The Kidney; Goldman-Cecil Medicine; Katzung's Basic and Clinical Pharmacology
This is a shared conversation. Sign in to Orris to start your own chat.